Tavilermide

Tavilermide is a selective, partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Trk Receptor

Research Areas >> Inflammation/Immunology

TrkA[1]

Tavilermide (MIM-D3) is a tyrosine kinase TrkA receptor agonist, which can be used to treat dry eye.Tavilermide is a proteolytically stable, cyclic peptidomimetic that has been shown to be a partial TrkA receptor agonist. Tavilermide demonstrates activities similar to NGF (but does not bind to the p75NTR receptor) and can potentiate the effects of suboptimal concentrations of NGF[1].

[1]. Meerovitch K, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275-85.

Entrectinib | LOXO-101 | ANA-12 | LM22B 10 | GW441756 | Repotrectinib | GNF-5837 | Altiratinib | LM22A-4 | Selitrectinib (LOXO-195) | Tyrphostin AG 879 | Belizatinib | AZ-23 | CH7057288 | CE-245677